ObjectiveTo study the clinical application value of screening cervical precancerous lesions of high risk human papillomavirus(HPV) testing combined with thin-prep cell test(TCT) in prevention of cervical intraepithelial neoplasma (CIN) and cervical carcinoma. MethodsSeven hundred and sixty-three women were screened by high risk HPV test, TCT and pathology test of biopsy more. The positive coincident rate with the pathology test positive rate during the three technologies was compared.ResultsHigh risk HPV positive was 287 cases, the rate of infection was 37.61％(287/763), and pathology test positive was 82 cases, the coincident rate of which was 28.57％ ( 82/287 ) ; TCT positive was 78 cases, the rate of infection was 10.22％ (78/763), and pathology test positive was 50 cases, the coincident rate of which was 64.10％ (50/78) ; TCT + high risk HPV positive was 59 cases, pathology test positive was 47 cases, and the coincident rate of which was 79.66％ (47/59). Among each coincident rate,the differences were statistically significant (P＜ 0.05). The positive rate of high risk HPV infection CIN I was 32.26％( 10/31 ),CIN Ⅱ 41.38％ (12/29), CIN Ⅲ 93.55％ (29/31), squamous carcinoma of the cervix 96.88％ (31/32),respectively. ConclusionsThe positive rate of high risk HPV increases significantly with the grade of cervical precancerous lesions. It is of great significance to screen in the population for HPV and TCT in a regular time span,since it could not only decrease HPV infection rate and the incidence of cervical lesions,but also prevent the cervical cancer.